E-ISSN 2636-865X
Research Article
The increased serum level of sRAGE is associated with multiple sclerosis but not with disability progression
1 Department of Clinical Biochemistry, Comenius University in Bratislava, Jessenius School of Medicine in Martin and University Hospital Martin, Martin, Slovakia  
2 Department of Neurology, Comenius University in Bratislava, Jessenius School of Medicine in Martin and University Hospital Martin, Martin, Slovakia  
3 Department of Medical Biochemistry and BioMed, Comenius University in Bratislava, Jessenius School of Medicine in Martin, Martin, Slovakia  
Neurol Sci Neurophysiol 2018; 35: 70-76
DOI: 10.5152/NSN.2018.9702
Key Words: Multiple sclerosis, disability progression, MSSS, sRAGE, serum level, biomarker
Abstract

 

Objective: It is still unclear as to why there are such large inter-individual variations in the risk and rate of disease disability progression of multiple sclerosis (MS). MS is a chronic autoimmune inflammatory disease of the central nervous system, with the involvement of autoimmunity, and inflammatory and neurodegenerative processes. In these processes, the important biologic function of receptors for advanced glycation end products (RAGE) could be altered by its circulating soluble form (sRAGE). The aim of our study was to investigate the possible role of sRAGE in the etiopathogenesis and disability progression of MS.

 

Methods: The serum level of sRAGE was determined using enzyme-linked immunosorbent assay (ELISA) in 44 patients with MS (22 rapidly progressing and 22 slow progressing) and 32 healthy controls from Slovakia.

 

Results: We showed a significantly increased serum level of sRAGE in patients with MS in comparison with the controls. We found no statistically significant differences in serum levels of sRAGE between the MS subgroup with rapid and slow disease disability progression, which was measured using the MSSS score.

 

Conclusion: Our results suggest a role of sRAGE in the etiopathogenesis of MS, but there was no association with disease disability progression. Further studies in larger cohorts of patients are necessary to clarify the exact mechanisms of the role of sRAGE in MS and its progression.

 

You may cite this article as: Cierny D, Michalik  J, Hanysova S, et al. The increased serum level of sRAGE is associated with multiple sclerosis but not with disability progression. Neurol Sci Neurophysiol 2018; 35: 70-76.

Key Words
Authors
All
Author's Corner
Survey
AVES | Copyright © 2018 Latest Update: 25.07.2018